Kate Amato Foundation Grant Awards
Stepwise Development of Acute Myeloid Leukemia in Germline GATA2 Deficiency Syndrome
2025Katelynn Wilton, MD, PhD
Boston Children’s Hospital and Harvard Medical School
Harnessing Therapeutic Probiotics to Enhance CAR-T Cell Activity in Pediatric Solid Tumors
2025Rosa Vincent, PhD
Baylor College of Medicine
Protein-Free Drug Inducible Transgene Expression Platform in CAR T Cells
2025Che-Hsing Li, PhD
Seattle Children’s Research Institute
Elucidating the Role of Extracellular Vesicles in Ewing Sarcoma Metastasis
2025Ingrid Lekk, PhD
Children’s Hospital Los Angeles
Advancing P27600: A Novel Plant-Derived Compound for Treating Ewing Sarcoma
2025Debananda Pati, PhD
Baylor College of Medicine and Texas Children’s Hospital
Elucidating distinct mechanisms of acquired resistance to HER2- and αvβ3- CAR-T cell therapies in pediatric rhabdomyosarcoma
2024Amanda Lulu
University of Virginia Children’s Hospital
Development of MIF-blocking GPC2 CAR T-cells for retinoblastoma
2024Guillem Pascual-Pasto, PhD
Childrens Hospital of Philadelphia
Transcriptomic and epigenetic reprogramming of CAR T cells using the MOTOR platform: an unbiased forward genomics approach
2024Azlann Arnett
Baylor College of Medicine
Targeting CTPS1 and nucleotide metabolism in MYC-amplified medulloblastoma
2023Myron Evans, PhD
Seattle Children’s Research Institute
RNA-nanoparticle (RNA-NP) vaccine for ARMS
2023Leighton Elliott, MD
University of Florida Pediatric Cancer Immunotherapy Initiative
Exploiting Aryl Hydrocarbon Receptor (AhR) as a Novel Therapeutic Strategy in MYCN-Amplified Neuroblastoma
2022Kanita Chaudry
University of Buffalo and Roswell Park Comprehensive Cancer Center
Identification of Genes Regulating NKT cell Anti-tumor Activity using a CRISPR/Cas9 Mutagenesis Screen
2022Gengwen Tian, MD, PhD
Baylor College of Medicine and Texas Children’s Cancer Center
Targeting mutant cohesin protein complex to treat relapsed pediatric Ewing Sarcoma
2021Debananda Pati, PhD
Texas Children’s Cancer Center and Baylor College of Medicine
Elucidating Molecular Mechanisms Underlying Exceptionally Wide Therapeutic Window for Small Molecule Allosteric Activators of Protein Phosphatase 2A
2020Ken Morita, MD, PhD
Dana-Farber Cancer Institute, Harvard Medical School
Selective cytotoxic effects of CDK12 inhibition on metastatic osteosarcoma cells
2020Matthew Harlow, PhD
Dana-Farber Cancer Institute, Harvard Medical School
Understanding the Role of MYCN-Driven FA Update to LIPID Metabolism and Tumor Growth to Identify a Targeted Approach for High-Risk MYCN-Amplified Neuroblastoma
2019Ling Tao, PhD
Texas Children’s Cancer Center, Baylor College of Medicine
Elucidating the Role of Invariant Natural Killer T Cells in Neuroblastoma Antitumor Immunity
2019Hamid Bassiri, MD
University of Pennsylvania and Children’s Hospital of Philadelphia (CHOP)
Transcriptional Addiction in Acute Myeloid Leukemia
2019Max Pimkin, MD, PhD
Dana Farber Cancer Institute, Boston Children’s Hospital, Harvard Medical School
The Role of the Macro lncRNA KCNQ1OT1 in Embryonal Rhabdomyosarcoma Tumorigenesis
2019Corrine Linardic, MD, PhD
Duke University School of Medicine
Developing a pediatric B-ALL model to uncover epigenetic mechanisms of relapse from CAR-T cell immunotherapy
2018Dr. Patricia Ernst and Dr. Terry Fry
Human Immunology and Immunotherapy Initiative at University of Colorado School of Medicine and Children’s Hospital of Colorado
The Role of CXCL 10-CXCR3 AXIS in Osteosarcoma Metastasis
2018Dr. Tsz-Kwong “Chris” Man
Cancer Genomics and Genetics Program at Baylor College of Medicine and Texas Children’s Cancer Center
Novel Targeted Therapy to Eliminate Leukemic Stem Cells in Pediatric Acute Myeloid Leukemia
2018Dr. Martina Roos, Dr. Vivian Chang and Dr. John Chute
The David Geffen School of Medicine at UCLA
